Irinotecan Hydrochloride CAS 100286-90-6 Ubunyulu ≥99.0% (HPLC) API USP Umgangatho oPhezulu wokuPhucuka
Ubonelelo lwabavelisi be-Irinotecan kunye nabaPhakathi abaNxulumeneyo:
Irinotecan Hydrochloride CAS: 100286-90-6
I-Irinotecan Isiseko sasimahla seCAS: 97682-44-5
Irinotecan Hydrochloride Trihydrate CAS: 136572-09-3
I-7-Ethyl-10-Hydroxycamptothecin CAS: 86639-52-3
I-1-Chlorocarbonyl-4-Piperidinopiperidine Hydrochloride CAS: 143254-82-4
| Igama leMchiza | Irinotecan Hydrochloride |
| Izithethantonye | Camptothecin II;CPT-II |
| Inombolo yeCAS | 100286-90-6 |
| Inombolo yeCAT | RF-API50 |
| Ubume beStokhwe | Kwi-Stock, iMveliso yoMveliso ukuya kwiiToni |
| Ifomula yeemolekyuli | I-C33H39ClN4O6 |
| Ubunzima beMolekyuli | 623.15 |
| Indawo yokunyibilika | 250-256℃ (dec.) |
| Iimeko zokuGcina | Phantsi koBubushushu be-Ambient |
| Uphawu | Ruifu Chemical |
| Into | Iinkcukacha |
| Imbonakalo | Umgubo oMhlophe okanye oMhlophe |
| Ukunyibilika | Inyibilika emanzini kunye ne-methanol, i-soluble kancinane kwi-chloroform, i-ethanol |
| Ukuchongwa kwe-IR | I-spectrum yokufunxa ye-infrared yesampulu yovavanyo kufuneka ihambelane naleyo yomgangatho wereferensi |
| Ukuchongwa kwe-HPLC | Ixesha lokugcinwa kwencopho enkulu yesisombululo sesampulu kufuneka ihambelane naleyo yomgangatho wereferensi. |
| Ukuchongwa | Iyahlangabezana neemfuno zovavanyo lweChloride Positive reaction |
| Ukufuma (KF) | 7.0%~9.0% w/w |
| Intsalela kwi-Ignition | ≤0.10% |
| Iintsimbi ezinzima | ≤20ppm |
| Irinotecan Hydrochloride Enantiomer | ≤0.10% (HPLC) |
| 7-Desethyl Irinotecan | ≤0.15% |
| I-Irinotecan Related Compound A | ≤0.15% |
| 11-Ethyl Irinotecan | ≤0.15% |
| Camptothecin | ≤0.15% |
| I-Irinotecan eNxulumene nayo iCompound B | ≤0.15% |
| 7-Ethylcanptothecin | ≤0.15% |
| I-7,11-Diethyl-10-Hydroxy Camptothecin | ≤0.15% |
| Nakuphi na Ukungcola Okungachazwanga | ≤0.10% |
| Ukungcola ngokupheleleyo | ≤0.50% |
| Intsalela yezinyibilikisi (GC) | |
| IMethanol | ≤2000ppm |
| I-acetone | ≤2000ppm |
| Dichloromethane | ≤500ppm |
| I-Peteoleum Ether: | ≤100ppm |
| I-Ethyl Acetate | ≤2000ppm |
| Benzeni | ≤2ppm |
| Iintsholongwane ze-Endotoxins | ≤0.29 EU/mg Irinotecan |
| Imida yeMicrobial | Ubalo lweAerobic Microbial iyonke: <1000 cfu/g |
| Ukungunda kunye negwele | <100 cfu/g |
| Ubunyulu / Indlela yokuHlalutya | ≥99.0% (HPLC, kwisiseko se-anhydrous) |
| Umgangatho woVavanyo | Umgangatho we-United States Pharmacopeia (USP). |
| Ukusetyenziswa | I-Active Pharmaceutical ingredient (API) |
Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, igubu lekhadibhodi, 25kg/Igubu, okanye ngokwemfuno yomthengi.
Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ekukhanyeni, ukufuma kunye nokuhlaselwa zizinambuzane.
I-lrinotecan hydrochloride (i-CAS 100286-90-6), i-semi-synthetic, ephuma emanzini ephuma kwi-agent ye-anticancer enamandla i-camptothecin, yasungulwa e-Japan kunyango lwemiphunga, i-ovarian, kunye nomhlaza womlomo wesibeleko.I-lrinotecan yenza umsebenzi wayo we-antitumor nge-inhibition ye-topoisomerase I, i-enzyme yeselula ebandakanyekayo ekugcineni i-topographic structure ye-DNA ngexesha lenkqubo yokuguqulela, ukukhutshelwa, kunye ne-mitosis.I-lrinotecan idlula kwi-de-esterification kwi-vivo ukuze ivelise i-metabolite esebenzayo, i-SN-38, ephindwe ka-1000 inamandla ngaphezu komzali.Unyango oludityanisiweyo lwe-irinotecan kunye nenye iarhente ye-anticancer esetyenziswa ngokubanzi, i-cisplatin, kuxelwe ukuba yongamile kune-arhente yodwa.I-lrinotecan ikulingo lwezonyango lwesisu, ibele, isikhumba, i-colorectal, i-pancreatic cancers, i-mesothelioma kunye ne-non-Hodgkin's lymphoma.
